Google

Sunday, April 3, 2011

New Biomarker for Tau Related Brain Disorders?


Penn Study Suggests Another Avenue for Detecting Alzheimer’s Disease...
Alzheimer's Reading Room

"As far as we know,
almost all neurodegenerative diseases
are characterized by the accumulation
of misfolded proteins
in the brain or spinal cord,"
Virginia M.-Y. Lee of the
University of Pennsylvania.
Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer’s disease and related disorders. The findings were published in the latest issue of Nature Communications.


Tau is one of the primary disease proteins associated with a suite of neurodegenerative diseases. Tau proteins are expressed primarily in the central nervous system where they help with the assembly and stability of microtubules, protein structures that are the backbone of the nerve-cell communication system.

“Acetylation was only detected in diseased brain tissue from patients with Alzheimer’s disease or frontotemporal degeneration, suggesting it may have a role in tau transformation linked to disease onset and progression,” says senior author Virginia M.-Y. Lee, PhD, director of Penn’s Center for Neurodegenerative Disease Research. “This suggests that one type of acetylation is a potential target for drug discovery and biomarker development for Alzheimer’s and related tauopathies.”

The researchers demonstrated that tau acetylation led to a loss of one of its major functions - to promote microtubule assembly, in addition to gaining a toxic function, pathological tau aggregation. Mass spectrometry analysis identified specific acetylation sites in the tau protein sequence that overlapped with known microtubule binding sequences, so acetylation may also play a role in faulty binding of tau to microtubules.

How normal tau becomes disengaged from microtubules to form disease-related clumps remains unknown. This study shows that acetylation is most likely another chemical modification implicated in neurodegenerative disorders to be explored as a potential way to detect and fight brain disease.

According to Lee, the next steps to follow up on this discovery are to pursue basic research into the mechanisms underlying this pathological acetylation of tau and its role in neurodegeneration in Alzheimer’s disease and related tauopathies. In addition, she noted that “Our highest priority will be to find ways to translate these findings into better diagnostics and therapeutics for patients with Alzheimer’s disease or frontotemporal degeneration.”

The first author of the study is Todd Cohen with Penn co-authors Jing Guo, David Hurtado, Linda Kwong, Ian Mills, and John Trojanowski.

This study was funded by the Association for Frontotemporal Degeneration and the National Institute on Aging.

http://www.uphs.upenn.edu/news/News_Releases/2011/04/alzheimers-tau-acetylation/
_______________________________________________

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4 billion enterprise.

Penn's School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools and among the top 10 schools for primary care. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $507.6 million awarded in the 2010 fiscal year.





Subscribe to the Alzheimer's Reading Room
Enter your email address:

Read More on the Alzheimer's Reading Room



The Alzheimer’s Action Plan: The Experts’ Guide to the Best Diag­no­sis and Treat­ment for Mem­ory Prob­lems
 
The 36-Hour Day A Family Guide to Caring for People with Alzheimer Disease


Original content Bob DeMarco, the Alzheimer's Reading Room